

# CITATION REPORT

List of articles citing

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

DOI: 10.1016/0304-3940(80)90178-0  
Neuroscience Letters, 1980, 20, 379-82.

**Source:** <https://exaly.com/paper-pdf/14873331/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
611	Synaptosomes prepared from fresh human cerebral cortex; morphology, respiration and release of transmitter amino acids. <b>1981</b> , 224, 419-25		35
610	D-aminophosphonovalerate is 100-fold more powerful than D-alpha-aminoadipate in blocking N-methylaspartate neurotoxicity. <b>1981</b> , 221, 207-10		59
609	Effects of chronic amphetamine treatment on the glutamate concentration in cerebrospinal fluid and brain: implications for a theory of schizophrenia. <i>Neuroscience Letters</i> , <b>1981</b> , 24, 93-6	3.3	29
608	Glutamic acid diethyl ester induces catalepsy in rats. A new model for schizophrenia?. <i>Neuroscience Letters</i> , <b>1982</b> , 34, 325-9	3.3	12
607	Inhibitory effects of dopamine on high affinity glutamate uptake from rat striatum. <b>1982</b> , 30, 1165-72		44
606	Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. <i>Neuroscience Letters</i> , <b>1982</b> , 28, 81-5	3.3	94
605	Glutamate in schizophrenics and healthy controls. <b>1982</b> , 231, 221-5		33
604	Rapid high-performance liquid chromatographic method for the assay of glutamine in human cerebrospinal fluid. <b>1983</b> , 274, 325-30		8
603	Genetic control of platelet glutaminase: a twin study. <b>1983</b> , 63, 292-3		2
602	Chemistry, physiology and neuropsychology of schizophrenia: towards an earlier diagnosis of schizophrenia I. <b>1983</b> , 233, 415-22		24
601	Increased [ <sup>3</sup> H]kainic acid binding in the prefrontal cortex in schizophrenia. <i>Neuroscience Letters</i> , <b>1983</b> , 40, 245-50	3.3	179
600	Chronic haloperidol administration enhances the gamma-aminobutyric acid level in the rat striatum without altering the glutamate level. <b>1984</b> , 23, 269-73		11
599	The cortico-nigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat. <b>1984</b> , 322, 124-6		130
598	Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. <b>1985</b> , 147, 276-82		97
597	Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. <b>1986</b> , 11, 157-198		1801
596	Presynaptic dopaminergic modulation of cortical input to the striatum. <b>1986</b> , 39, 699-74		157
595	Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. <b>1986</b> , 90, 123-30		104

594 On the construction of effectiveness of interaction tables. **1986**, 20, 3

593 Glutamate receptors and schizophrenia. **1987**, 1, 217-21

11

592 Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. **1987**, 20, 337-45

64

591 Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. **1987**, 22, 291-301

44

590 Antagonism of AP-5- and amphetamine-induced behaviour by timelotem as compared with clozapine and haloperidol. **1987**, 41, 1909-14

11

589 Glutamate and glutamine in cerebrospinal fluid and serum from healthy volunteers--analytical aspects. **1988**, 424, 378-84

26

588 Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers. **1988**, 23, 689-97

57

587 Glutamatergic abnormality in schizophrenia. **1988**, 1, 144-146

2

586 Current biological research in schizophrenia. **1989**, 2, 123-36

585 Release of glutamate and of free fatty acids in vasogenic brain edema. **1989**, 70, 578-91

106

584 An hypothesis regarding the antipsychotic effect of neuroleptic drugs. **1989**, 32, 337-45

19

583 [<sup>3</sup>H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. **1989**, 77, 231-6

230

582 Excitotoxicity and N-methyl-D-Aspartate receptors. **1989**, 17, 299-319

46

581 Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulphiride treatment. **1989**, 99, 322-7

25

580 Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. **1989**, 52, 1781-6

346

579 Excitatory amino acids and neuropsychiatric disorders. **1989**, 26, 505-25

278

578 Schizophrenia, tardive dyskinesia, and brain GABA. **1989**, 25, 200-6

23

577 Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. **1989**, 155, 305-16

143

576	Excitotoxic amino acids and neuropsychiatric disorders. <b>1990</b> , 30, 47-71	352
575	MK-801-induced stereotypy and its antagonism by neuroleptic drugs. <b>1990</b> , 81, 173-82	126
574	Glutamate and schizophrenia. <b>1990</b> , 11, 357	8
573	Glutamate: a new target in schizophrenia?. <b>1990</b> , 11, 219-20	78
572	Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. <b>1990</b> , 39, 25-32	208
571	Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. <b>1990</b> , 13, 272-6	919
570	Reply. <b>1990</b> , 13, 326-327	0
569	Reply. <b>1990</b> , 13, 327	2
568	Antagonism of AP-5-induced sniffing stereotypy links umespirone to atypical antipsychotics. <b>1991</b> , 48, 499-505	8
567	Aspergillus antigen latex test for diagnosis of invasive aspergillosis. <b>1991</b> , 338, 1023-4	23
566	Nausea and vasopressin. <b>1991</b> , 338, 1023	14
565	Pharmacotoxic psychosis after memantine in Parkinson's disease. <b>1991</b> , 338, 1022-3	53
564	Cerebrospinal fluid biochemical correlates of behavior in partial epilepsy. <b>1991</b> , 4, 81-85	2
563	Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. <b>1991</b> , 337, 450-2	197
562	Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. <b>1991</b> , 41, 1-24	1522
561	Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. <b>1991</b> , 30, 1191-8	64
560	Evidence of glutamatergic deficiency in schizophrenia. <i>Neuroscience Letters</i> , <b>1991</b> , 121, 77-80	3.3 139
559	A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis. <b>1991</b> , 16, 1099-111	91

558	Smithkline Beecham Prize for Young Psychopharmacologists: A review of the relationship between calcium channels and psychiatric disorders. <b>1992</b> , 6, 462-82	7
557	The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. <b>1992</b> , 36, 91-131	36
556	N-methyl-D-aspartate antagonists, schizophrenia, and neuroleptic malignant syndrome. <b>1992</b> , 49, 900-1	9
555	A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. <b>1992</b> , 38, 329-33	31
554	Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization. <b>1992</b> , 50, 1673-81	36
553	NMDA-associated glycine binding site increases in schizophrenic brains. <b>1992</b> , 32, 379-81	34
552	Developments in the drug treatment of schizophrenia. <b>1992</b> , 13, 116-21	130
551	Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. <b>1992</b> , 42, 273-82	63
550	The modulation of dopaminergic transmission in the striatum by MK-801 is independent of presynaptic mechanisms. <b>1992</b> , 31, 1111-4	28
549	Equivalent EEG sources determined by FFT approximation in healthy subjects, schizophrenic and depressive patients. <b>1992</b> , 4, 207-13	15
548	In vitro and in vivo characterization of the NMDA receptor-linked strychnine-insensitive glycine site. <b>1992</b> , 12, 157-62	12
547	Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. <b>1992</b> , 89, 1-10	102
546	The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. <b>1992</b> , 87, 23-35	54
545	Distribution of glial fibrillary acidic protein and glutamine synthetase in human cerebral cortical astrocytes--a light and electron microscopic study. <b>1993</b> , 22, 893-902	26
544	Phencyclidine treatment in mice: effects on phencyclidine binding sites and glutamate uptake in cerebral cortex preparations. <b>1993</b> , 93, 47-59	11
543	D-aspartate binding to the glutamate uptake site in human brain tissue--effects of leucotomy. <b>1993</b> , 94, 147-52	5
542	Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. <b>1993</b> , 92, 57-65	26
541	Clozapine improves dizocilpine-induced delayed alteration impairment in rats. <b>1993</b> , 94, 223-33	23

540	The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of D1 and D2 dopamine receptor blockers in the rat. <b>1993</b> , 110, 165-8	26
539	The sigma receptor ligand 1,3-di-(2-tolyl)guanidine in animal models of schizophrenia. <b>1993</b> , 233, 261-7	16
538	Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampus. <b>1993</b> , 235, 305-7	15
537	Metabotropic excitatory amino acid receptor agonists selectively potentiate behavioral effects induced by ionotropic excitatory amino acid receptor agonists in mice. <b>1993</b> , 250, 9-13	4
536	Ultrastructural features of biopsied temporopolar cortex (area 38) in a case of schizophrenia. <b>1993</b> , 10, 15-27	28
535	A familial/genetic study of plasma serine and glycine concentrations. <b>1993</b> , 34, 221-5	11
534	Pressure-induced disorders in neurotransmission and spontaneous behavior in rats: an animal model of psychosis. <b>1993</b> , 34, 622-9	8
533	Excitatory amino acid receptors in schizophrenia. <b>1993</b> , 19, 105-17	75
532	31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. <b>1993</b> , 19, 35-53	90
531	Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. <b>1994</b> , 14, 4159-66	197
530	Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice. <b>1994</b> , 95, 223-33	14
529	d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. <b>1994</b> , 95, 105-11	62
528	Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5-HIAA levels in the dorsolateral striatum of conscious rats: an in vivo microdialysis study. <b>1994</b> , 95, 145-55	26
527	Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. <b>1994</b> , 115, 147-56	113
526	Further notes on Craven's conjecture. <i>Social Choice and Welfare</i> , <b>1994</b> , 11, 283	0.7 2
525	Capillary zone electrophoretic determination of organic acids in cerebrospinal fluid from patients with central nervous system diseases. <b>1994</b> , 680, 243-6	27
524	D-cycloserine decreases both D1 and D2 dopamine receptors number and their function in rat brain. <b>1994</b> , 48, 351-6	6
523	In vivo effects of local and systemic phencyclidine on the extracellular levels of catecholamines and transmitter amino acids in the dorsolateral striatum of anaesthetized rats. <b>1994</b> , 150, 109-15	30

522	Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients. <b>1994</b> , 36, 31-4		30
521	Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. <b>1994</b> , 35, 84-95		102
520	Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. <b>1994</b> , 633, 337-42		111
519	Excitatory amino acids: implications for psychiatric disorders research. <b>1994</b> , 55, 1683-99		38
518	Glutamatergic drugs in Parkinson's disease. <b>1994</b> , 55, 2067-75		38
517	Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. <b>1994</b> , 18, 859-70		40
516	Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains. <i>Neuroscience Letters</i> , <b>1994</b> , 177, 39-43	3-3	26
515	Activities of Glutathione Reductase, S-Transferase, and Peroxidase in Schizophrenic Patients. <b>1994</b> , 48, 247-250		2
514	Neurotransmitter systems in schizophrenia. <b>1995</b> , 38, 305-39		12
513	Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, amino acids, and free radicals in gerbil brain after cerebral ischemia. <b>1995</b> , 26, 43-52		19
512	Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. <b>1995</b> , 122, 15-26		197
511	The selective 5-HT <sub>2A</sub> receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse—implications for psychosis. <b>1995</b> , 100, 225-37		79
510	Modulation of the NMDA Receptor Complex by D-Cycloserine. <b>1995</b> , 1, 74-90		3
509	Glycine Site Agonists of the NMDA Receptor: A Review. <b>1995</b> , 1, 227-260		38
508	Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease?. <b>1995</b> , 19, 533-52		86
507	New insights into the biology of schizophrenia through the mechanism of action of clozapine. <b>1995</b> , 13, 177-213		101
506	The effect of phencyclidine on the basal and high potassium evoked extracellular GABA levels in the striatum of freely-moving rats: an in vivo microdialysis study. <b>1995</b> , 671, 54-62		21
505	Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. <b>1995</b> , 674, 82-90		126

504	MonthlyUpdateCentral & Peripheral Nervous Systems: Pharmacotherapeutic Potential for Compounds Acting at NMDA Receptors: Update 1995. <b>1995</b> , 4, 475-485	2
503	Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. <b>1995</b> , 52, 829-36	375
502	New approaches to the drug treatment of schizophrenia. <b>1995</b> , 32, 461-503	17
501	Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynureate, in rats. <b>1995</b> , 280, 37-45	9
500	Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. <b>1995</b> , 284, 129-34	12
499	The pentadecapeptide [Ser1]histogranin impairs passive avoidance learning in mice. <b>1995</b> , 283, 251-4	
498	Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. <b>1995</b> , 29, 211-23	178
497	Glutamate receptor dysfunction and schizophrenia. <b>1995</b> , 52, 998-1007	1335
496	Neuropsychophysiological study of children at risk for schizophrenia: a preliminary report. <b>1995</b> , 34, 1284-91	38
495	Glycine therapy of schizophrenia: some caveats. <b>1996</b> , 39, 155-6	10
494	Psychosis and vulnerability to ECT-induced seizures. <b>1996</b> , 62, 191-201	4
493	The development of psychosis in epilepsy: a re-examination of the kindling hypothesis. <b>1996</b> , 75, 59-66	29
492	Modulatory role of dopamine on excitatory amino acid receptors. <b>1996</b> , 20, 659-71	8
491	Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. <b>1996</b> , 58, 721-34	104
490	Dopamine-N-methyl-D-aspartate interactions in the modulation of locomotor activity and memory consolidation in mice. <b>1996</b> , 308, 1-12	40
489	Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. <b>1996</b> , 40, 57-62	123
488	Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. <b>1996</b> , 65, 171-8	37
487	Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. <b>1996</b> , 169, 610-7	197

486	A dose-response analysis of the behavioral effects of (+)MK-801 in guinea pig: comparison with CPP. <b>1996</b> , 53, 799-807		16
485	The GABAB-receptor antagonist, CGP 35348, antagonises gamma-hydroxybutyrate- and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice. <b>1996</b> , 103, 1255-63		45
484	Neurotransmission and the ontogeny of human brain. <b>1996</b> , 103, 403-19		28
483	Increased density of entorhinal glutamate-immunoreactive vertical fibers in schizophrenia. <b>1996</b> , 103, 503-7		39
482	Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755. <b>1996</b> , 103, 117-29		27
481	Majority-consistent preference orderings. <i>Social Choice and Welfare</i> , <b>1996</b> , 13, 259-267	0.7	6
480	Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. <b>1996</b> , 381, 245-8		455
479	Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia. <b>1997</b> , 31, 17-26		11
478	Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. <b>1997</b> , 17, 2921-7		1370
477	MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. <b>1997</b> , 335, 107-16		53
476	Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. <b>1997</b> , 338, 185-90		7
475	Glutamate in schizophrenia: clinical and research implications. <b>1997</b> , 27, 157-68		82
474	The Glutamate Hypothesis of Schizophrenia. <b>1997</b> , 7, 47-67		15
473	Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [ <sup>18</sup> F]fluorodeoxyglucose (FDG). <b>1997</b> , 7, 9-24		271
472	Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). <b>1997</b> , 7, 25-38		295
471	Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. <b>1997</b> , 41, 636-43		80
470	In vitro <sup>1</sup> H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. <b>1997</b> , 42, 359-66		44
469	Deficits of [ <sup>3</sup> H]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. <i>Neuroscience Letters</i> , <b>1997</b> , 232, 13-6	3.3	30

- 468 Cholecystinin B receptor antagonists enhance the locomotor response to the N-methyl-D-aspartate antagonists phencyclidine and dizocilpine maleate. **1997**, 76, 1057-67 10
- 467 GABA- and glutamate-evoked responses in the rat ventral pallidum are modulated by dopamine. **1997**, 9, 1397-406 39
- 466 Dopamine/glutamate interactions in Parkinson's disease. **1997**, 21, 393-400 110
- 465 A two-process theory of schizophrenia: evidence from studies in post-mortem brain. **1997**, 31, 277-95 61
- 464 Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. **1997**, 751, 217-31 142
- 463 Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. **1997**, 759, 205-12 137
- 462 Antipsychotic drug effects on glutamatergic activity. **1997**, 764, 46-52 42
- 461 Effect of chronic clozapine administration on [3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas. **1997**, 762, 216-8 22
- 460 A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. **1997**, 56, 797-802 95
- 459 Effect of antipsychotic drugs on the gene expression of NMDA receptor subunits in rats. **1997**, 22, 249-52 16
- 458 Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. **1997**, 104, 761-6 64
- 457 Glycine and D-serine decrease MK-801-induced hyperactivity in mice. **1997**, 104, 1195-205 49
- 456 M100907, a selective 5-HT<sub>2A</sub> receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. **1998**, 18, 197-209 61
- 455 M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. **1998**, 19, 74-85 53
- 454 Psychotic disorder after lamotrigine. **1998**, 19, 124-5 7
- 453 Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats. **1998**, 357, 466-71 25
- 452 The glutamate hypothesis of schizophrenia. **1998**, 23, 243-6 14
- 451 Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis- and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment. **1998**, 51, 92-100 21

450	Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. <i>Neuroscience Letters</i> , <b>1998</b> , 241, 143-6	33	40
449	GABA and brain abnormalities in schizophrenia. <b>1998</b> , 82, 25-35		17
448	In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. <b>1998</b> , 44, 382-98		61
447	Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. <b>1998</b> , 44, 667-74		62
446	The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. <b>1998</b> , 8, 141-52		102
445	The neuroanatomy and neurochemistry of schizophrenia. <b>1998</b> , 21, 57-75		21
444	Absence of basal ganglia amino acid neuron deficits in schizophrenia in three collections of brains. <b>1998</b> , 31, 167-75		6
443	Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. <b>1998</b> , 281, 1349-52		802
442	Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. <b>1998</b> , 31 Suppl 2, 92-103		53
441	Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. <b>1998</b> , 65, 446-53		520
440	Biological research on schizophrenia. <b>1998</b> , 52 Suppl, S170-2		9
439	Dopaminergic sensitization of rats with and without early prefrontal lesions: implications for the pathogenesis of schizophrenia. <b>1999</b> , 2, 271-281		4
438	Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. <b>1999</b> , 10, 59-90		122
437	Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia?. <b>1999</b> , 40, 140-1		1
436	Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. <b>1999</b> , 24, 369-74		48
435	Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. <b>1999</b> , 359, 280-7		27
434	Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. <b>1999</b> , 145, 61-6		67
433	Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates. <b>1999</b> , 146, 67-72		28

432	NMDA receptor antagonists acting at the glycineB site in rat models for antipsychotic-like activity. <b>1999</b> , 106, 1189-204	16
431	Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. <b>1999</b> , 33, 513-21	198
430	Does MK-801 discrimination constitute an animal model of schizophrenia useful for detecting atypical antipsychotics?. <b>1999</b> , 64, 429-33	8
429	The concept of target features in schizophrenia research. <b>1999</b> , 395, 2-11	76
428	The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. <b>1999</b> , 20, 201-25	1014
427	Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. <b>1999</b> , 20, 106-18	442
426	Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. <b>1999</b> , 34, 266-76	38
425	Neurotransmitter interactions in schizophrenia-therapeutic implications. <b>1999</b> , 249 Suppl 4, 37-43	55
424	Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. <b>1999</b> , 56, 29-36	389
423	Intra-striatal phencyclidine inhibits N-methyl-D-aspartic acid-stimulated increase in glutamate levels of freely moving rats. <b>1999</b> , 23, 161-74	7
422	D2 dopamine receptor but not AMPA and kainate glutamate receptor genes show altered expression in response to long term treatment with trans- and cis-flupenthixol in the rat brain. <b>1999</b> , 68, 14-21	4
421	Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. <b>1999</b> , 45, 68-75	33
420	Neurochemical brain imaging investigations of schizophrenia. <b>1999</b> , 46, 600-15	78
419	Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. <b>1999</b> , 46, 161-72	152
418	Neurotransmitter interactions in schizophrenia--therapeutic implications. <b>1999</b> , 46, 1388-95	213
417	Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. <b>1999</b> , 46, 1060-80	24
416	NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. <b>1999</b> , 10, 461-5	77
415	D-Cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function. <b>2000</b> , 11, 631-7	13

414	Blockade of the serotonergic system counteracts the dizocilpine-induced changes in dopaminergic function. <b>2000</b> , 11, 29-36	9
413	Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. <b>2000</b> , 12, 3721-8	390
412	Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. <b>2000</b> , 25, 131-7	80
411	Effects of (S)-ketamine on striatal dopamine: a [ <sup>11</sup> C]raclopride PET study of a model psychosis in humans. <b>2000</b> , 34, 35-43	182
410	Activation of striatal group II metabotropic glutamate receptors has a differential effect on dopamine-D1 and -D2 receptor antagonist-induced hypokinesia in the rat. <b>2000</b> , 361, 289-97	11
409	The role of glutamate receptors in antipsychotic drug action. <b>2000</b> , 19, 87-94	38
408	Positive modulators of the AMPA receptor. <b>2000</b> , 10, 1539-1548	4
407	Blockade of NMDA receptors in the amygdala prevents latent inhibition of fear-conditioning. <b>2000</b> , 7, 393-9	49
406	Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. <b>2000</b> , 100, 1-9	22
405	Network interactions in schizophrenia - therapeutic implications. <b>2000</b> , 31, 342-9	165
404	Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. <b>2000</b> , 98, 163-75	65
403	The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. <b>2000</b> , 66, 2427-32	44
402	Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT(2C/2B) receptor antagonists: neurochemical and behavioural studies. <b>2000</b> , 39, 2318-28	70
401	Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate (Ant)agonists. <b>2000</b> , 34, 788-97	11
400	Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. <b>2001</b> , 47, 99-103	37
399	Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. <b>2001</b> , 41, 237-60	605
398	Increased cortical kynurenate content in schizophrenia. <b>2001</b> , 50, 521-30	466
397	Current and novel approaches to the drug treatment of schizophrenia. <b>2001</b> , 44, 477-501	115

396	A systems model of altered consciousness: integrating natural and drug-induced psychoses. <b>2001</b> , 56, 495-507		198
395	Pharmacology and behavioral pharmacology of the mesocortical dopamine system. <b>2001</b> , 63, 241-320		372
394	Differential effects of chlorpromazine on ionotropic glutamate receptors in cultured rat hippocampal neurons. <i>Neuroscience Letters</i> , <b>2001</b> , 305, 53-6	3-3	15
393	Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. <i>Neuroscience Letters</i> , <b>2001</b> , 313, 96-8	3-3	357
392	Chlorpromazine prolongs the deactivation of N-methyl-D-aspartate-induced currents in cultured rat hippocampal neurons. <i>Neuroscience Letters</i> , <b>2001</b> , 315, 1-4	3-3	3
391	Searching for schizophrenia genes. <b>2001</b> , 7, 169-74		49
390	Platelet glutamate receptor supersensitivity in major depressive disorder. <b>2001</b> , 24, 129-32		51
389	Effects of benztropine on ketamine-induced behaviors in Cebus monkeys. <b>2001</b> , 12, 293-8		7
388	A behavioural pattern analysis of hypoglutamatergic mice--effects of four different antipsychotic agents. <b>2001</b> , 108, 1181-96		56
387	Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. <b>2001</b> , 41, 294-300		11
386	The platelet as a peripheral marker in psychiatric illness. <b>2001</b> , 16, 229-236		47
385	Glutamate and its role in psychiatric illness. <b>2001</b> , 16, 139-146		34
384	NMDA receptor regulation of memory and behavior in humans. <b>2001</b> , 11, 529-42		205
383	Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. <b>2001</b> , 6, 634-46		124
382	Effects of single and repeated phencyclidine administration on the expression of metabotropic glutamate receptor subtype mRNAs in rat brain. <b>2001</b> , 25, 173-84		19
381	[Glutamatergic neurotransmission in schizophrenics]. <b>2001</b> , 69 Suppl 2, S56-61		8
380	The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. <b>2001</b> , 158, 1367-77		745
379	Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. <b>2002</b> , 136, 319-27		43

378	Glutamatergic mechanisms in schizophrenia. <b>2002</b> , 42, 165-79	515
377	Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors. <b>2002</b> , 113, 1-10	34
376	Amino Acid Transmitter Systems. 587-600	4
375	The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. <b>2002</b> , 2, 8	88
374	Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. <b>2002</b> , 27, 826-33	58
373	Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies. <b>2002</b> , 366, 417-24	18
372	Phencyclidine supersensitivity in rats with neonatal dopamine loss. <b>2002</b> , 161, 255-62	19
371	Differential changes in glutamate concentration in the primate prefrontal cortex during spatial delayed alternation and sensory-guided tasks. <b>2002</b> , 145, 133-41	24
370	Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. <b>2002</b> , 83, 1241-51	175
369	NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. <b>2002</b> , 7, 837-44	360
368	Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?. <b>2002</b> , 25, 191-212	38
367	Alterations in NMDA receptor subunit levels in the brain regions of rats chronically administered typical or atypical antipsychotic drugs. <b>2003</b> , 28, 919-24	15
366	Evaluating glutamatergic transmission in schizophrenia. <b>2003</b> , 1003, 113-8	42
365	Glutamatergic animal models of schizophrenia. <b>2003</b> , 1003, 131-7	121
364	GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. <b>2003</b> , 110, 803-12	46
363	The neuroanatomy of schizophrenia: circuitry and neurotransmitter systems. <b>2003</b> , 3, 77-107	36
362	Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. <b>2003</b> , 97, 153-79	255
361	Glutamate receptor genes as candidates for schizophrenia susceptibility. <b>2003</b> , 60, 137-151	6

360	N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case-control analyses. <b>2003</b> , 119B, 24-7		24
359	Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions. <b>2003</b> , 38, 661-70		61
358	The platelet window: examining receptor regulated second messenger processes in psychosis and depression. <b>2003</b> , 15, 309-15		1
357	Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence. <b>2003</b> , 17, 1306-12		25
356	Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. <b>2003</b> , 47, 285-94		19
355	Conventional and atypical antipsychotics in the elderly : a review. <b>2003</b> , 23, 287-322		28
354	Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. <i>Neuroscience Letters</i> , <b>2003</b> , 347, 81-4	3-3	63
353	Protein kinase C is involved in clozapine's facilitation of N-methyl-D-aspartate- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex. <b>2003</b> , 118, 501-12		19
352	The influence of adenosine A3 receptor agonist: IB-MECA, on scopolamine- and MK-801-induced memory impairment. <b>2003</b> , 141, 11-7		32
351	Motor effects of amphetamine in rats pretreated with either dizocilpine or phencyclidine. <b>2003</b> , 147, 211-5		5
350	A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. <b>2003</b> , 13, 271-8		86
349	[Glutamatergic hypothesis of schizophrenia]. <b>2003</b> , 25, 177-83		22
348	Störungen der Neurotransmission als Grundlage psychiatrischer Erkrankungen. <b>2003</b> , 123-140		2
347	Schizophrenieähnliche Störungen und nichtorganische Wahnerkrankungen. <b>2003</b> , 1123-1149		
346	The etiopathogenesis of schizophrenias. <b>2004</b> , 37 Suppl 2, S103-12		11
345	Neuregulin 1 and schizophrenia. <b>2004</b> , 36, 62-71		103
344	Coupling between neuronal and glial cells via glutamate metabolism in brain of healthy persons and patients with mental disorders. <b>2004</b> , 69, 705-19		8
343	Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. <b>2004</b> , 6, 79-90		34

342	Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. <b>2004</b> , 52, 114-22	54
341	Cannabis-associated psychosis: current status of research. <b>2004</b> , 18, 895-910	47
340	Mitochondria, synaptic plasticity, and schizophrenia. <b>2004</b> , 59, 273-96	139
339	Endogenous kynurenic acid disrupts prepulse inhibition. <b>2004</b> , 56, 255-60	143
338	Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. <b>2004</b> , 69, 237-53	141
337	Schizophrenia as a disorder of neuroplasticity. <b>2004</b> , 59, 19-45	53
336	A neurobehavioral screening of the ckr mouse mutant: implications for an animal model of schizophrenia. <b>2004</b> , 62, 315-26	23
335	Atypical antipsychotics and the relevance of glutamate and serotonin. <b>2004</b> , 14, 259-65	39
334	Chronic nicotine causes functional upregulation of ionotropic glutamate receptors mediating hippocampal noradrenaline and striatal dopamine release. <b>2004</b> , 44, 293-301	52
333	Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. <b>2005</b> , 11, 3561-94	53
332	Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. <b>2005</b> , 16, 1363-7	32
331	Platelet Glutamate Receptors as a Window into Psychiatric Disorders. <b>2005</b> , 233-241	1
330	Activation of noradrenergic locus coeruleus neurons by clozapine and haloperidol: involvement of glutamatergic mechanisms. <b>2005</b> , 8, 329-39	25
329	An ionotropic but not a metabotropic glutamate agonist potentiates the pharmacological effects of olanzapine in the rat. <b>2005</b> , 16, 635-42	2
328	Phenotype of schizophrenia: a review and formulation. <b>2005</b> , 10, 27-39	219
327	No evidence for association between polymorphisms in GRM3 and schizophrenia. <b>2005</b> , 5, 23	41
326	Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. <b>2005</b> , 5, 6	83
325	Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. <b>2005</b> , 177, 256-63	55

324	Neurochemical changes in LPA1 receptor deficient mice--a putative model of schizophrenia. <b>2005</b> , 30, 371-7	56
323	Effects of haloperidol and clozapine on glutamate release from nerve terminals isolated from rat prefrontal cortex. <b>2005</b> , 56, 12-20	16
322	Novel Potential Therapeutics for Schizophrenia: Focus on the Modulation of Metabotropic Glutamate Receptor Function. <b>2005</b> , 3, 9-34	20
321	Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. <b>2005</b> , 30, 1324-33	81
320	Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS. <b>2005</b> ,	10
319	Dysfunction of Glia-Neuron Communication in Pathophysiology of Schizophrenia. <b>2005</b> , 1, 151-163	62
318	Glutamatergic dysfunction in OCD. <b>2005</b> , 30, 1735-40	272
317	Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. <b>2005</b> , 14, 1947-54	156
316	Neurodevelopment, neuroplasticity, and new genes for schizophrenia. <b>2005</b> , 147, 319-45	100
315	Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. <b>2005</b> , 58, 724-30	132
314	NMDA receptor subunit NR1 and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. <b>2005</b> , 80, 323-30	134
313	Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. <b>2005</b> , 80, 315-22	181
312	Dopamine and Glutamate in Psychiatric Disorders. <b>2005</b> ,	5
311	Schizophrenia-associated neural growth factors in peripheral blood. A review. <b>2006</b> , 16, 469-80	24
310	Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. <b>2006</b> , 6, 1017-38	56
309	Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. <b>2006</b> , 56, 2-13	145
308	Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective. <b>2006</b> , 139, 153-71	64
307	Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. <b>2006</b> , 63, 366-73	124

306	Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. <b>2006</b> , 1086, 160-8	53
305	Possible mechanisms of neurodegeneration in schizophrenia. <b>2006</b> , 31, 1279-94	76
304	Isolation rearing or methamphetamine traumatization induce a "dysconnection" of prefrontal efferents in gerbils: implications for schizophrenia. <b>2006</b> , 113, 365-79	28
303	Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. <b>2006</b> , 113, 557-71	44
302	Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics. <b>2006</b> , 173, 234-42	21
301	Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. <b>2006</b> , 10, 131-48	183
300	Paradoxical effects of very low dose MK-801. <b>2006</b> , 537, 77-84	9
299	Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. <b>2006</b> , 1089, 186-94	57
298	Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. <b>2006</b> , 84, 259-65	21
297	Alterations of plasma and cerebrospinal fluid glutamate levels in rats treated with the N-methyl-D-aspartate receptor antagonist, ketamine. <b>2006</b> , 20, 628-33	30
296	Schizophrenie und verwandte Störungen <b>Neurobiologie</b> . <b>2006</b> , 345-386	2
295	Neurogenetics of Psychiatric Disorders. <b>2007</b> ,	
294	Dopamine and Glutamate Hypotheses of Schizophrenia. <b>2007</b> ,	
293	ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders. <b>2007</b> , 64, 863-876	11
292	Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling. <b>2007</b> , 180, 152-60	62
291	Alterations in serum amino acid concentrations in male and female schizophrenic patients. <b>2007</b> , 380, 186-90	29
290	The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. <b>2007</b> , 93, 109-16	84
289	Neuropsychiatric Disorders An Integrative Approach. <b>2007</b> ,	4

288	Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. <b>2007</b> , 95, 174-8	44
287	Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. <b>2007</b> , 61, 162-6	117
286	The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. <b>2007</b> , 269-80	72
285	Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites. <b>2007</b> , 19, 45-52	10
284	Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. <b>2007</b> , 1152, 215-27	44
283	Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. <b>2007</b> , 53, 260-70	95
282	From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission. <b>2007</b> , 55, 17-54	189
281	[Immunology in schizophrenic disorders]. <b>2007</b> , 78, 253-6, 258-60, 262-3	16
280	Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats. <b>2007</b> , 114, 885-91	14
279	Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. <b>2008</b> , 258, 16-27	76
278	Modulation of ligand-gated ion channels by antidepressants and antipsychotics. <b>2007</b> , 35, 160-74	23
277	Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT <sub>2A</sub> agonist and NMDA antagonist model of psychosis. <b>2008</b> , 200, 573-83	28
276	Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review. <b>2008</b> , 115, 493-511	44
275	A psychoneuroimmunological perspective to Emil Kraepelin's dichotomy: schizophrenia and major depression as inflammatory CNS disorders. <b>2008</b> , 258 Suppl 2, 97-106	93
274	Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. <b>2008</b> , 32, 1014-23	242
273	A protein interaction based model for schizophrenia study. <b>2008</b> , 9 Suppl 12, S23	9
272	Age-related differential sensitivity to MK-801-induced locomotion and stereotypy in C57BL/6 mice. <b>2008</b> , 580, 161-8	16
271	Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. <b>2008</b> , 91, 47-58	81

270	Dysregulation of glutamate carboxypeptidase II in psychiatric disease. <b>2008</b> , 99, 324-32	35
269	Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. <b>2008</b> , 99, 218-24	58
268	Baseline temperature in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. <b>2008</b> , 93, 437-43	16
267	Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. <b>2008</b> , 106, 89-107	252
266	High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. <b>2008</b> , 102, 88-95	63
265	Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. <b>2008</b> , 60, 358-403	190
264	Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. <b>2008</b> , 12, 1497-507	27
263	Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). <b>2008</b> , 326, 209-17	188
262	Quetiapine: treatment for substance abuse and drug of abuse. <b>2008</b> , 65, 611-8	30
261	COX-2 inhibition in schizophrenia and major depression. <b>2008</b> , 14, 1452-65	84
260	Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia. <b>2008</b> , 1, 6	193
259	Psychopharmacological modeling of psychiatric illness. 252-270	
258	Can models of reinforcement learning help us to understand symptoms of schizophrenia?. <b>2009</b> , 249-269	
257	Role of the cholinergic system in the pathology and treatment of schizophrenia. <b>2009</b> , 9, 73-86	31
256	A family-based association study of DNA sequence variants in GRM7 with schizophrenia in an Indonesian population. <b>2009</b> , 12, 1283-9	24
255	Effects of phencyclidine on auditory gating in the rat hippocampus and the medial prefrontal cortex. <b>2009</b> , 1298, 153-60	14
254	The dopamine and glutamate theories of schizophrenia: A short review. <b>2009</b> , 20, 240-241	7
253	GLT-1 upregulation impairs prepulse inhibition of the startle reflex in adult rats. <b>2009</b> , 57, 703-13	35

252	Deficient NRG1-ERBB signaling alters social approach: relevance to genetic mouse models of schizophrenia. <b>2009</b> , 1, 302-12	29
251	Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. <b>2009</b> , 111, 891-900	73
250	Dissection of phenotype reveals possible association between schizophrenia and Glutamate Receptor Delta 1 (GRID1) gene promoter. <b>2009</b> , 111, 123-30	53
249	The Neuroimmunological Basis of Behavior and Mental Disorders. <b>2009</b> ,	8
248	Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. <b>2009</b> , 10, 127-55	54
247	Dissecting the Molecular Causes of Schizophrenia. <b>2009</b> , 51-79	
246	Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. <b>2009</b> , 12, 501-12	40
245	Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. <b>2010</b> , 212, 155-70	44
244	Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia. <b>2010</b> , 40, 467-77	10
243	Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats. <b>2010</b> , 639, 67-80	26
242	Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. <b>2010</b> , 639, 59-66	46
241	The neurobiology of schizophrenia: new leads and avenues for treatment. <b>2010</b> , 20, 810-5	20
240	Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. <b>2010</b> , 34, 958-77	124
239	When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits. <b>2010</b> , 217, 324-33	120
238	Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. <b>2010</b> , 113, 287-302	106
237	DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patients--support for the glutamate hypothesis of schizophrenias. <b>2010</b> , 9, 489-97	22
236	Role of metabotropic glutamate receptors in CNS disorders. 321-379	8
235	Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia?. 141-168	4

234	Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation. <b>2011</b> , 44, 33-48	13
233	De novo truncating mutation in Kinesin 17 associated with schizophrenia. <b>2010</b> , 68, 649-56	41
232	Rare variants create synthetic genome-wide associations. <b>2010</b> , 8, e1000294	693
231	Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: a possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia. <b>2010</b> , 58, 1174-8	9
230	Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. <b>2011</b> , 127, 3-13	146
229	Dysbindin C-A-T haplotype is associated with thicker medial orbitofrontal cortex in healthy population. <b>2011</b> , 55, 508-13	10
228	Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. <b>2011</b> , 216, 247-54	72
227	The effects of selective antagonists of serotonin 5-HT <sub>7</sub> and 5-HT <sub>1A</sub> receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. <b>2011</b> , 220, 83-90	62
226	Prenatal exposure to PCP produces behavioral deficits accompanied by the overexpression of GLAST in the prefrontal cortex of postpubertal mice. <b>2011</b> , 220, 132-9	17
225	Changes in gene expression after phencyclidine administration in developing rats: a potential animal model for schizophrenia. <b>2011</b> , 29, 351-8	25
224	Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. <b>2011</b> , 68, 665-74	114
223	Altered levels of glutamatergic receptors and Na <sup>+</sup> /K <sup>+</sup> ATPase- $\alpha$ 1 in the prefrontal cortex of subjects with schizophrenia. <b>2011</b> , 128, 7-14	63
222	Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. <b>2011</b> , 5, 1	116
221	Neurobiological background for the development of new drugs in schizophrenia. <b>2011</b> , 34, 111-26	31
220	Editorial [Hot topic: Novel Potential Therapeutic Approaches for Schizophrenia (Executive Guest Editor: Kenji Hashimoto)]. <b>2011</b> , 17, 135-135	
219	The phenotype of recurrent 10q22q23 deletions and duplications. <b>2011</b> , 19, 400-8	52
218	Recent advances in psychoneuroimmunology: Inflammation in psychiatric disorders. <b>2011</b> , 2,	16
217	mGlu2/3 Agonists $\alpha$ New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial. <b>2011</b> , 41, 559-566	0

216	(+)-(S)-trujillon, (+)-(S)-4-(2,2-diphenyl-1,3,2-oxazabolidin-5-oxo)propionic acid, a novel glutamatergic analog, modifies the activity of globus pallidus neurons by selective NMDA receptor activation. <b>2011</b> , 23, 429-37	7
215	Concentration of calcium and magnesium and trace elements (zinc, copper, iron and manganese) in cerebrospinal fluid: a try of a pathophysiological classification. <b>2011</b> , 25 Suppl 1, S45-9	12
214	Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?. <b>2011</b> , 11, 565-74	86
213	Targeting of metabotropic glutamate receptors for the treatment of schizophrenia. <b>2011</b> , 17, 94-102	33
212	Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. <b>2011</b> , 17, 130-6	67
211	Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. <b>2011</b> , 1, e55	155
210	The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus. <b>2012</b> , 37, 364-77	45
209	Glutamatergic animal models of schizophrenia. <b>2012</b> , 18, 1593-604	29
208	Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). <b>2013</b> , 19, 1311-20	26
207	From glutamatergic dysfunction to cognitive impairment: boundaries in the therapeutic of the schizophrenia. <b>2012</b> , 13, 1543-8	8
206	The Integration of the Glutamatergic and the White Matter Hypotheses of Schizophrenia's Etiology. <b>2012</b> , 10, 2-11	5
205	Mapping prodromal psychosis: a critical review of neuroimaging studies. <b>2012</b> , 27, 181-91	58
204	Reversal learning and attentional set-shifting in mice. <b>2012</b> , 62, 1168-74	69
203	Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?. <b>2012</b> , 62, 1371-80	35
202	Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. <b>2012</b> , 62, 1473-83	79
201	Role of the anterior thalamic nucleus in the motor hyperactivity induced by systemic MK-801 administration in rats. <b>2012</b> , 62, 2440-6	15
200	N-methyl-D-aspartate receptor 2B subunit (GRIN2B) gene variation is associated with alerting, but not with orienting and conflicting in the Attention Network Test. <b>2012</b> , 63, 259-65	6
199	NMDA receptor and schizophrenia: a brief history. <b>2012</b> , 38, 920-6	274

198	From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. <b>2012</b> , 37, 4-15	660
197	35Pregnanolone glutamate, a use-dependent NMDA antagonist, reversed spatial learning deficit in an animal model of schizophrenia. <b>2012</b> , 235, 82-8	12
196	Reliable biomarkers and predictors of schizophrenia and its treatment. <b>2012</b> , 35, 645-59	24
195	The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. <b>2012</b> , 26, 663-90	159
194	Preweaning sensorimotor deficits and adolescent hypersociability in Grin1 knockdown mice. <b>2012</b> , 34, 159-73	21
193	Synaptic dysfunction in schizophrenia. <b>2012</b> , 970, 493-516	52
192	Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions. <b>2012</b> , 120, 396-407	24
191	Cross-diagnostic comparison of duration mismatch negativity and P3a in bipolar disorder and schizophrenia. <b>2012</b> , 14, 239-48	54
190	Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. <b>2012</b> , 219, 25-34	32
189	Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia. <b>2013</b> , 248, 252-60	17
188	Involvement of the primate specific gene G72 in schizophrenia: From genetic studies to pathomechanisms. <b>2013</b> , 37, 2410-7	17
187	Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. <b>2013</b> , 23, 931-40	50
186	Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects. <b>2013</b> , 47, 1247-53	51
185	Role of Lysophosphatidic Acid (LPA) in Behavioral Processes: Implications for Psychiatric Disorders. <b>2013</b> , 451-473	3
184	Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis. <b>2013</b> , 74, 48-58	40
183	Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. <b>2013</b> , 42, 5-19	97
182	What can we learn about schizophrenia from studying the human model, drug-induced psychosis?. <b>2013</b> , 162B, 661-70	47
181	Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats. <b>2013</b> , 122, 10-6	29

180	Neurotransmitters, Psychotropic Drugs and Microglia: Clinical Implications for Psychiatry. <b>2013</b> , 20, 331-344	4
179	NMDA Receptor Activity in Neuropsychiatric Disorders. <b>2013</b> , 4, 52	85
178	Animal models for predicting the efficacy and side effects of antipsychotic drugs. <b>2013</b> , 35 Suppl 2, S132-9	31
177	The neuroimmunology of schizophrenia. <b>2013</b> , 11, 107-17	44
176	Os possíveis papéis da S100B na esquizofrenia. <b>2013</b> , 40, 35-40	2
175	Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. <b>2014</b> , 40 Suppl 2, S152-8	51
174	Antipsychotics and the Dopamine-Serotonin Connection. <b>2014</b> , 1-49	1
173	[The glutamate hypothesis of schizophrenia]. <b>2014</b> , 82, 447-56	8
172	Evidence of Glutamatergic Dysfunction in the Pathophysiology of Schizophrenia. <b>2014</b> , 265-294	5
171	Impaired working memory by repeated neonatal MK-801 treatment is ameliorated by galantamine in adult rats. <b>2014</b> , 725, 32-9	23
170	Combination of neonatal PolyI:C and adolescent phencyclidine treatments is required to induce behavioral abnormalities with overexpression of GLAST in adult mice. <b>2014</b> , 258, 34-42	16
169	Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. <b>2014</b> , 48, 304-13	141
168	Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders. <b>2014</b> ,	2
167	The synapse in schizophrenia. <b>2014</b> , 39, 1059-67	37
166	Implementation of two-dimensional L-COSY at 7 Tesla: an investigation of reproducibility in human brain. <b>2014</b> , 40, 1319-27	12
165	Auditory hallucinations: A review of the ERC "VOICE" project. <b>2015</b> , 5, 193-209	53
164	Cannabinoids and schizophrenia. <b>2015</b> , 193-204	1
163	Glutamate and dopamine in schizophrenia: an update for the 21st century. <b>2015</b> , 29, 97-115	428

162	Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. <b>2015</b> , 58, 7888-94		37
161	Psychiatry and Neuroscience Update. <b>2015</b> ,		0
160	BIOMARKERS AND CAUSATIVE FACTORS OF SCHIZOPHRENIA. <b>2016</b> , 4, 78-85		2
159	Investigation of Dysregulation of Several MicroRNAs in Peripheral Blood of Schizophrenia Patients. <b>2016</b> , 14, 256-60		25
158	SYNGAP1: Mind the Gap. <b>2016</b> , 10, 32		49
157	Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence. <b>2016</b> , 7, 422		60
156	Treating Schizophrenia With the Diuretic Bumetanide: A Case Report. <b>2016</b> , 39, 115-7		36
155	Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia. <i>Neuroscience Letters</i> , <b>2016</b> , 633, 87-93	3-3	16
154	Proteomic systems evaluation of the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology. <b>2016</b> , 177, 98-107		8
153	Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment. <b>2016</b> , 157, 10-27		43
152	The Therapeutic Role of d-Cycloserine in Schizophrenia. <b>2016</b> , 76, 39-66		8
151	GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders. <b>2017</b> , 99, e1		10
150	Interaction of Dopamine and Glutamate Release in the Primate Prefrontal Cortex in Relation to Working Memory and Reward. <b>2017</b> , 77-102		0
149	Comparative analysis of MBD-seq and MeDIP-seq and estimation of gene expression changes in a rodent model of schizophrenia. <b>2017</b> , 109, 204-213		14
148	Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator. <b>2017</b> , 174, 370-385		10
147	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. <b>2017</b> , 18, 330-356		22
146	New drug developments in psychosis: Challenges, opportunities and strategies. <b>2017</b> , 152, 3-20		43
145	Putative Role of Endocannabinoids in Schizophrenia. <b>2017</b> , 83-113		

144	A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway. <b>2017</b> , 7,	10
143	Theranostic Biomarkers for Schizophrenia. <b>2017</b> , 18,	53
142	New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis. <b>2017</b> , 18,	106
141	The DLGAP family: neuronal expression, function and role in brain disorders. <b>2017</b> , 10, 43	72
140	Can Models of Reinforcement Learning Help Us to Understand Symptoms of Schizophrenia?. <b>2017</b> , 261-275	
139	Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. <b>2018</b> , 265, 25-38	42
138	Agmatine-attenuated cognitive and social deficits in subchronic MK-801 model of schizophrenia in rats. <b>2018</b> , 28, 245-253	5
137	A-582941, cholinergic alpha 7 nicotinic receptor agonist, improved cognitive and negative symptoms of the sub-chronic MK-801 model of schizophrenia in rats. <b>2018</b> , 28, 4-13	3
136	Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis. <b>2018</b> , 44, 807-823	44
135	General Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms. <b>2018</b> , 126, 208-216	12
134	Mutations of the glycine cleavage system genes possibly affect the negative symptoms of schizophrenia through metabolomic profile changes. <b>2018</b> , 72, 168-179	5
133	N-acetylcysteine attenuates the cuprizone-induced behavioral changes and oligodendrocyte loss in male C57BL/7 mice via its anti-inflammation actions. <b>2018</b> , 96, 803-816	13
132	Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia. <b>2018</b> , 4, 134-148	17
131	Association of the Synapse-Associated Protein 97 () Gene Polymorphism With Neurocognitive Function in Schizophrenic Patients. <b>2018</b> , 9, 458	9
130	Adenosine Promotes the Recovery of Mice from the Cuprizone-Induced Behavioral and Morphological Changes while Effecting on Microglia and Inflammatory Cytokines in the Brain. <b>2018</b> , 13, 412-425	7
129	Comparative Studies of Glutamine Synthetase Levels in the Brains of Patients with Schizophrenia and Mentally Healthy People. <b>2018</b> , 12, 95-101	4
128	Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3 $\beta$ /Catenin pathway. <b>2018</b> , 391, 1327-1338	11
127	Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis. <b>2018</b> , 43, 2249-2255	22

126	Gut microbiome and magnetic resonance spectroscopy study of subjects at ultra-high risk for psychosis may support the membrane hypothesis. <b>2018</b> , 53, 37-45	54
125	Effect of pre- and post-treatment with (Brahmi) on phencyclidine-induced disruptions in object recognition memory and cerebral calbindin, parvalbumin, and calretinin immunoreactivity in rats. <b>2019</b> , 15, 1103-1117	6
124	Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory. <b>2019</b> , 33, 1274-1287	5
123	The Role of Biomarkers in Psychiatry. <b>2019</b> , 1118, 135-162	14
122	The Pharmacology of Visual Hallucinations in Synucleinopathies. <b>2019</b> , 10, 1379	18
121	Evaluation of Clinical Factors Associated with Adverse Drug Events in Patients Receiving Sub-Anesthetic Ketamine Infusions. <b>2019</b> , 12, 3413-3421	10
120	Candidate metabolic biomarkers for schizophrenia in CNS and periphery: Do any possible associations exist?. <b>2020</b> , 226, 95-110	7
119	Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. <b>2020</b> , 19, 15-33	124
118	Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development. <b>2020</b> , 223, 59-70	12
117	Memory Impairments and Psychosis Prediction: A Scoping Review and Theoretical Overview. <b>2020</b> , 30, 521-545	5
116	Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach. <b>2020</b> , 9, 100154	14
115	Modulations in the ATPases during ketamine-induced schizophrenia and regulatory effect of "3-(3, 4-dimethoxy phenyl) -1- (4-methoxyphenyl) prop-2-en-1-one": an and studies. <b>2020</b> , 40, 148-156	5
114	NMDAR Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice. <b>2020</b> , 88, 603-613	14
113	Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study. <b>2021</b> , 11,	1
112	Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure. <b>2021</b> , 403, 113144	4
111	Do NMDA-R antagonists re-create patterns of spontaneous gamma-band activity in schizophrenia? A systematic review and perspective. <b>2021</b> , 124, 308-323	11
110	Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry. <b>2021</b> , 128, 735-747	1
109	Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders. <b>2021</b> , 12, 703452	6

108	Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders. <b>2021</b> , 22,	0
107	Applications of innovative technologies to the delivery of antipsychotics. <b>2021</b> ,	0
106	A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia. <b>2021</b> , 22,	0
105	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of H-magnetic resonance spectroscopy studies. <b>2021</b> ,	6
104	Taurine prevents MK-801-induced shoal dispersion and altered cortisol responses in zebrafish. <b>2021</b> , 111, 110399	2
103	Antipsychotic Agents. <b>2003</b> , 599-672	5
102	Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective. 5-35	4
101	15 Glutathione in the Nervous System: Roles in Neural Function and Health and Implications for Neurological Disease. <b>2007</b> , 347-399	9
100	Redox Dysregulation in Schizophrenia: Genetic Susceptibility and Pathophysiological Mechanisms. <b>2009</b> , 285-311	9
99	Cytokines, Immunity and Schizophrenia with Emphasis on Underlying Neurochemical Mechanisms. <b>2009</b> , 307-325	4
98	Mitochondrial Complex I as a Possible Novel Peripheral Biomarker for Schizophrenia. <b>2009</b> , 71-83	1
97	Glutamate-Dopamine Balance in the Striatum: Pre- and Post-Synaptic Interactions. <b>1994</b> , 475-489	9
96	Pharmacology of Excitatory Amino Acid Antagonists and their Possible Therapeutic Use in Neurological Disease. <b>1988</b> , 63-77	1
95	Co-Regulation and Epigenetic Dysregulation in Schizophrenia and Bipolar Disorder. <b>2012</b> , 281-347	3
94	Human Freedom, Reasoned Will, and the Brain: The Bereitschaftspotential Story. <b>2003</b> , 283-320	19
93	Viral Mechanisms of Schizophrenia. <b>2000</b> , 79-102	3
92	Glutamatergic, Cholinergic, and GABAergic Systems in Posterior Cingulate Cortex: Interactions and Possible Mechanisms of Limbic System Disease. <b>1993</b> , 557-580	4
91	Schizophrenia Treatment Strategies. <b>1996</b> , 1-34	1

90	Glutamate and Schizophrenia and the N-Methyl-d-Aspartate Receptor Hypofunction Hypothesis. <b>2005</b> , 169-179	1
89	Dopamine Receptors and the Treatment of Schizophrenia. <b>2010</b> , 431-477	5
88	The Pathophysiological Basis of Parkinson's Disease. <b>1993</b> , 25-50	9
87	The Glutamatergic System as a Target of Antipsychotic Drug Action. <b>1991</b> , 289-293	3
86	Atypical Antipsychotic Drugs: Clinical and Preclinical Studies. <b>1996</b> , 77-115	6
85	Decreased Spinal Fluid Monoamine Metabolites and Norepinephrine in Schizophrenic Patients with Brain Atrophy. <b>1985</b> , 88-95	3
84	The Role of Dopamine in the Control of Neurobiological Functions. <b>1989</b> , 1-17	5
83	The Dopaminergic and Glutamatergic Systems in Schizophrenia. <b>1990</b> , 714-720	3
82	Das dopaminerg-glutamaterge Gleichgewicht unter dem Aspekt von schizophrener Plus- und Minussymptomatik. <b>1990</b> , 119-126	9
81	PREDICTION OF ANTIPSYCHOTIC ACTIVITY. <b>1993</b> , 87-98	1
80	Developmental models and hypothesis-driven early interventions in schizophrenia. <b>2004</b> , 455-472	1
79	Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia. <b>2002</b> , 22, 333-4	2
78	Glutamate Receptors in Schizophrenia and Antipsychotic Drugs. <b>2000</b> , 121-136	3
77	Npas4: a neuronal transcription factor with a key role in social and cognitive functions relevant to developmental disorders. <b>2012</b> , 7, e46604	79
76	Metabolomic analysis reveals metabolic disturbance in the cortex and hippocampus of subchronic MK-801 treated rats. <b>2013</b> , 8, e60598	21
75	Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy. <b>2020</b> , 18, 197-208	2
74	Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia. <b>2020</b> , 20, 2404-2421	4
73	Metabotropic glutamate receptors: potential drug targets for psychiatric disorders. <b>2010</b> , 4, 20-36	25

72	Role of Neurochemicals in Schizophrenia. <b>2020</b> , 9, 144-161	2
71	Neurotransmission. <b>2007</b> , 81-100	2
70	The Phencyclidine/N-Methyl-D-Aspartate (PCP/ NMDA) Model of Schizophrenia: Theoretical and Clinical Implications. <b>1993</b> , 23, 135-143	4
69	Neuroimaging Bipolar Illness With Positron Emission Tomography and Magnetic Resonance Imaging. <b>1997</b> , 27, 489-495	18
68	Prenatal Complications, Genetic Vulnerability, and Schizophrenia: The New England Longitudinal Studies of Schizophrenia. <b>1999</b> , 29, 151-156	21
67	Using transcription factors for direct reprogramming of neurons. <b>2019</b> , 11, 431-444	4
66	A Selective Review of the Excitatory-Inhibitory Imbalance in Schizophrenia: Underlying Biology, Genetics, Microcircuits, and Symptoms. <b>2021</b> , 9, 664535	2
65	The Dopamine Hypothesis of Schizophrenia: New Aspects. <b>2002</b> , 417-422	0
64	Aktuelle Forschungsaspekte zur Ätiopathogenese der Schizophrenien. <b>2003</b> , 195-204	
63	The Biology of Schizotaxia. <b>2004</b> , 339-353	1
62	Role of Glycine in Schizophrenia. <b>2005</b> , 181-195	
61	Störungen der Neurotransmission und Signaltransduktion als Grundlage psychischer Erkrankungen. <b>2008</b> , 157-183	
60	Schizophrene Psychosen. <b>2008</b> , 1255-1358	
59	Disinhibition of Prefrontal Cortex Neurons in Schizophrenia. <b>2010</b> , 99-111	
58	Entzündliche Veränderungen als gemeinsame Pathogenese affektiver und schizophrener Erkrankungen. <b>2010</b> , 59-91	
57	Störungen der Neurotransmission und Signaltransduktion als Grundlage psychischer Erkrankungen. <b>2011</b> , 217-250	
56	Mapping Prodromal Psychosis. <b>2011</b> , 445-471	1
55	Die kortiko-nigrale Projektion benutzt Glutamat als Transmitter. <b>1985</b> , 946-948	

- 54 Bemerkungen zur Situation der Klassifikation endogener Psychosen. **1986**, 11-25
- 53 Phencyclidin und das glutamaterge System. **1986**, 176-180 6
- 52 Psychopharmakologie [Grundlagen]. **1987**, 357-387
- 51 Biologische Konzepte zur Biologie und Pathogenese der Schizophrenien [Eine Übersicht]. **1988**, 3-8
- 50 Striatale Mechanismen der Verhaltenssteuerung: Die Rolle von Dopamin, Azetylcholin und Glutamat. **1988**, 209-210
- 49 Phencyclidine [A Challenge to Schizophrenia Research]. **1990**, 515-518
- 48 Interfering with glutamatergic neurotransmission by means of MK-801 administration discloses the locomotor stimulatory potential of other transmitter systems in rats and mice. **1990**, 476-487 2
- 47 Role of excitatory amino acid neurotransmission in synaptic plasticity and pathology. An integrative hypothesis concerning the pathogenesis and evolutionary advantages of schizophrenia-related genes. **1990**, 29, 39-48 3
- 46 Behavioural Pharmacology of Brain Glutamate. **1990**, 427-432
- 45 The Treatment of Positive and Negative Schizophrenic Symptoms with Dopamine Agonists. **1991**, 377-398 3
- 44 Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis. **1991**, 34, 203-10 9
- 43 Anatomische, biochemische und funktionelle Strukturen physiologischer Neurotransmitter-Regelkreise. **1991**, 1-18
- 42 Die glutamatergen und sigmaergen Systeme bei den Schizophrenien. **1991**, 147-157 1
- 41 Dopaminagonisten zur Schizophrenie-Behandlung: Ein neues therapeutisches Wirkprinzip?. **1992**, 250-255
- 40 Neuronale Verschaltungen. **1992**, 249-271
- 39 Alternative approaches to the discovery of novel antipsychotic agents. **1992**, 38, 299-336 9
- 38 Anmerkungen zur Glutamat-Hypothese der Schizophrenien. **1993**, 8-12
- 37 Verteilung von Kainatrezeptoren im menschlichen Gehirn. **1993**, 774-777

36	Involvement of transmitter systems in neuropsychiatric diseases. <b>1993</b> , 87, 18-21	8
35	The neurochemistry of schizophrenia. <b>1994</b> , 4, 133-59	2
34	31P Magnetic Resonance Spectroscopy Study of Brain Metabolism in Schizophrenia. <b>1995</b> , 227-251	1
33	Dopaminerges System und Verhalten: Zur psychopathologischen Relevanz cortico-striato-thalamo-corticaler "Circuits" <b>1996</b> , 265-271	2
32	Bedeutung der Glutamat-Rezeptor-Subtypen für psychiatrische Erkrankungen. <b>1998</b> , 10-15	
31	Modellvorstellungen zur "Pathogenese der Schizophrenien. <b>1998</b> , 3-21	
30	Schizophrenia. <b>1999</b> , 527-541	
29	Translating the Glutamatergic Hypothesis of Schizophrenia Through Homeostatic Regulation of Brain Glycine. <b>2015</b> , 353-373	
28	CHAPTER 6:Drugs that Target the Glutamate Synapse: Implications for the Glutamate Hypothesis of Schizophrenia. <b>2015</b> , 115-140	
27	The Hypothesis of "Hyperia" from the Perspective of Neuronal Plasticity. <b>2016</b> , 05, 17-26	
26	Störungen der Neurobiochemie und Signaltransduktion als Grundlage psychischer Erkrankungen. <b>2016</b> , 1-35	
25	[Comparative study of glutamate dehydrogenase in the brain of patients with schizophrenia and mentally healthy people]. <b>2017</b> , 117, 101-107	0
24	Störungen der Neurobiochemie und Signaltransduktion als Grundlage psychischer Erkrankungen. <b>2017</b> , 245-278	
23	The Glutamatergic System as Potential Clinical Biomarkers for Blood and Cerebrospinal Fluid Monitoring. <b>2018</b> , 507-521	
22	PHARMACOLOGICAL PROFILE OF DIZOCILPINE (MK-801) AND ITS POTENTIAL USE IN ANIMAL MODEL OF SCHIZOPHRENIA. <b>2019</b> , 88, 166-179	
21	Perspective Chapter - NMDA Treatments for CNS Disorders.	
20	Schizophrenie, Entzündung und glutamaterge Neurotransmission: ein pathophysiologisches Modell. <b>2006</b> , 93-123	
19	Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. <b>1993</b> , 18, 157-72	20

18	Memantine: a review of possible uses in child and adolescent psychiatry. <b>2013</b> , 22, 166-71	29
17	Elevated glutamate, glutamine and GABA levels and reduced taurine level in a schizophrenia model using an in vitro proton nuclear magnetic resonance method. <b>2019</b> , 11, 5919-5931	2
16	Autoimmune Psychosis. <b>2022</b> , 503-526	1
15	Glutamate and N-Acetylaspartate Alterations Observed in Early Phase Psychosis: A Systematic Review of Proton Magnetic Resonance Spectroscopy Studies.. <b>2022</b> , 321, 111459	
14	Neuroinflammation in Schizophrenia: The Key Role of the WNT/ECatenin Pathway.. <b>2022</b> , 23,	2
13	Abnormal synaptic plasticity and impaired cognition in schizophrenia.. <b>2022</b> , 12, 541-557	0
12	Video_1.mp4. <b>2019</b> ,	
11	Video_2.mp4. <b>2019</b> ,	
10	Majority-consistent preference orderings. <i>Social Choice and Welfare</i> , <b>1996</b> , 13, 259-267	0.7 1
9	Potential diagnostic biomarkers for schizophrenia. <b>2022</b> ,	
8	Commentary on Monoamine oxidase and its inhibitors in relation to antidepressive activity by E. Albert Zeller. <b>2023</b> , 137-143	0
7	Molecular mechanisms underlying cannabis-induced risk of psychosis. <b>2022</b> , 197-242	0
6	The role of integrin beta in schizophrenia: a preliminary exploration. 1-27	0
5	Hair zinc levels and psychosis risk among adolescents. <b>2022</b> , 8,	0
4	Glutamatergic dysfunction in Schizophrenia. <b>2022</b> , 12,	2
3	The medial prefrontal cortex and the cardiac baroreflex activity: physiological and pathological implications. <b>2023</b> , 475, 291-307	0
2	Children with Early-Onset Psychosis Have Increased Burden of Rare GRIN2A Variants. <b>2023</b> , 14, 779	0
1	Dietary monosodium glutamate increases visceral hypersensitivity in a mouse model of visceral pain.	0

